Need for Third-Party Discovery Favors Discretionary Denial of Post Grant Review

Feb 22, 2021

Reading Time : 3 min

Patent owner NCS Multistage Inc. filed patent infringement lawsuits against several companies in the Western District of Texas alleging infringement of U.S. Patent 10,465,445 (the “’445 patent”). These included suits against Nine Energy Service, Inc. (the “Nine litigation”) and TCO AS (the “TCO litigation”). On August 8, 2020, TCO filed a petition for post grant review of the ’445 patent. At institution, the board considered patent owner’s argument advocating for discretionary denial under 35 U.S.C. section 324(a).

As an initial matter, the board addressed whether the factors related to the Director’s discretion to deny institution identified in its precedential decision Apple Inc. v. Fintiv, Inc. applied to the present post grant review (PGR). The board found that although Fintiv involved the Director’s discretion pursuant to Section 314(a), which concerns inter partes review (IPR), and did not specifically extend its application to Section 324(a), which is the relevant statute that applies to PGR, the pertinent statutory language providing the Director with discretion to deny institution is the same in both sections. Moreover, the policy considerations associated with discretion to deny institution—including inefficiency, duplication of effort and the risk of inconsistent results—apply equally to PGRs. Therefore, the board applied the Fintiv factors to the present PGR.

The board first addressed Fintiv factors 1-5 and concluded that several of those factors favored denial of institution in view of the Nine and TCO litigations. Specifically, the board found that the proximity of the court’s trial date to the board’s Final Written Decision under factor 2 weighed in favor of denial because the Nine litigation was scheduled to commence four months before the Final Written Decision was due. The board also held under factor 3 that there had been considerable investment in the Nine litigation, with the parties having exchanged infringement and invalidity contentions and substantial document production and the court having held a Markman hearing. Moreover, under factor 4 the board concluded that although the PGR challenged two claims—claims 26 and 56—not involved in the Nine and TCO litigations, the PGR was directed to substantially the same claims, as well as the same grounds, as the parallel proceedings, especially considering patent owner’s stipulation that it would not assert claims 26 and 56 against petitioner. The board found that only factor 5, which evaluates whether the petitioner and defendant in the parallel proceeding are the same party, weighed against denial because petitioner was not a party to the Nine litigation.

The board then turned to Fintiv factor 6, which allows it to assess “other circumstances” that impact its exercise of discretion, including the merits. Under this factor, the board considered petitioner’s allegation of invalidating prior sales and use of its product, called the TDP-PO plug, by a third-party foreign entity and whether any necessary discovery on that issue might impact the proceeding. The patent owner contended that these allegations involved “highly fact-intensive issues” and argued that the “critical discovery that will need to be conducted to determine if the [alleged sales and public use] qualify as invalidating prior art” weighed in favor of denial. Petitioner countered that no “hypothetical discovery” is needed to decide the prior sales/use issue and that patent owner will have an opportunity to challenge petitioner’s evidence and depose its declarant. The board ultimately agreed with patent owner, and in doing so explained that the district court is the better forum to flesh out these “unusual” issues involving third-party discovery.

The board also determined that an initial review of the merits suggested that petitioner’s invalidity challenges were weak—weighing in favor of discretionary denial. Specifically, the board found that petitioner’s indefiniteness and written description challenges, which questioned the interpretation of the claim term “the rupture disc is . . . configured to rupture when exposed to a rupturing force greater than the rupture burst pressure,” were belied by the district court’s entry of a construction for that term. The board also held that petitioner’s obviousness challenges were flawed because they failed to map the prior art to a claim limitation and did not provide sufficient reasoning to combine the asserted references.

The board ultimately determined that, as a whole, the Fintiv factors suggested that inefficient duplication of efforts was likely and warranted denial of institution.

Practice Tip: When bringing an IPR or PGR, a petitioner should consider whether any of its invalidity challenges raise issues that could require excessive or unique types of discovery, including discovery from a third party or foreign entity. A petitioner should be aware that including such challenges makes the petition more susceptible to discretionary denial.

TCO AS v. NCS Multistage Inc., PGR2020-00077, Paper 16 (PTAB Feb. 18, 2021) (Cocks, Browne, Worth)

Share This Insight

Previous Entries

IP Newsflash

May 27, 2025

The Federal Circuit affirmed a District of Delaware finding of non-infringement in an ANDA litigation due to the patentee’s clear and unmistakable disavowal of claim scope during prosecution. Specifically, the court held that statements made during prosecution of a parent application before the asserted claims were allowed amounted to a prosecution disclaimer that extended to subsequent patents in the family. In reaching this conclusion, the court rejected an attempt by the patentee to resurrect the claim scope through a unilateral, self-serving statement made in later applications in the family.

...

Read More

IP Newsflash

May 13, 2025

The Federal Circuit recently affirmed a district court’s holding that patent term extension (PTE) for a reissued patent was properly based on the issue date of the original patent and not that of the reissued patent. The Federal Circuit concluded that, where both the original and reissued patents claimed a drug product under regulatory review, using the issue date of the original patent to calculate PTE comports with both the purpose of the Hatch-Waxman Act and the related statutory context.

...

Read More

IP Newsflash

May 12, 2025

The Patent Trial and Appeal Board recently declined to institute a petition for IPR that was filed on the same day that the petitioner filed another petition challenging the same claims of the same patent. The board was not persuaded by petitioner’s arguments that a second petition was needed due to alleged claim construction issues or the number, length or scope differences of the challenged claims.

...

Read More

IP Newsflash

May 9, 2025

The USPTO Director vacated the board’s decision to institute inter partes review based on an erroneous application of the Fintiv factors. Specifically, the Director found that the board placed too much emphasis on Petitioner’s Sotera stipulation, and not enough emphasis on the investment in the parallel litigation. Weighing the factors as a whole, the Director determined that institution should be denied.

...

Read More

IP Newsflash

May 9, 2025

In an institution decision following the USPTO’s withdrawal of its Fintiv Memo, the board addressed discretionary denial of an IPR under Fintiv in view of a parallel ITC investigation. The board noted it would not consider the now-rescinded June 2022 memo from then-director Vidal which instructed that the PTAB would not deny institution of an IPR or PGR under Fintiv when the request is based on a parallel ITC investigation. The board conducted a Fintiv analysis in view of the ITC investigation, but ultimately determined that discretionary denial was not warranted in this particular situation.

...

Read More

IP Newsflash

April 23, 2025

The Federal Circuit recently refused to apply collateral estoppel to claims of a patent asserted in district court litigation based on a Patent Trial and Appeal Board (PTAB) decision finding similar claims from the same patent unpatentable because the PTAB applied a lower burden of proof than what is required to invalidate claims in district court.

...

Read More

IP Newsflash

April 7, 2025

The Central District of California denied a defendant’s motion to dismiss or transfer plaintiff’s first-filed declaratory judgment action based on defendant’s later-filed patent infringement suit in Wisconsin.  Though suit was seemingly imminent when defendant advised plaintiff it might be infringing defendant’s patents, plaintiff responded by requesting a licensing agreement in lieu of litigation. The court found that plaintiff’s action was not anticipatory forum-shopping litigation because plaintiff only filed suit after defendant neglected to respond to its licensing offer.

...

Read More

IP Newsflash

April 1, 2025

The District of Delaware recently denied in part a motion to compel production of documents and testimony between a patentee and potential investors, valuation firms and an international bank based on the common interest exception. In so doing, the court reaffirmed that disclosure of privileged information to third parties will generally waive privilege unless it can be shown that the parties’ interests are identical and the communications are legal, not solely commercial.

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.